

Daily Research Report

Dt.: 21 Sep, 2026

INDEX	NIFTY	BANKNIFTY	USDINR
Outlook	Neutral	Neutral	Neutral

INSTITUTIONAL TRADING ACTIVITY IN CRS.

Category	Buy Value	Sell Value	Net Value
FII	38461.63	37862.09	+599.54
DII	17310.04	16290.34	+1019.69

TRADE STATISTICS FOR 18/09/2026

Instrument	No. of Contracts	Turnover (Cr.)	Put Call Ratio
Index Fut.	50032	7895.64	
Stock Fut.	918980	60451.08	
Index Opt.	86461175	13182815	0.98
Stock Opt.	8025250	543879.9	
F&O Total	95455437	13795042	

Nifty Action: 18/09/2026



PIVOT TABLE					
	R2	R1	PIVOT	S1	S2
NIFTY	23449	23394	23340	23292	23238
BANKNIFTY	56733	56454	56309	56122	55866

NIFTY FUT.			
	TRIGGER	T1	T2
Above	23550	23710	23895
Below	23180	23022	22857

BANK NIFTY FUT.			
	TRIGGER	T1	T2
Above	57000	58050	58672
Below	56000	55654	55278

NIFTY CHART



Occurrence of an 'Inside Bar' near broadening-pattern support indicates an attempt to stabilize, with 23110 emerging as immediate support and 23340 as the immediate trigger for a potential short-squeeze rally towards 23700 (20-DEMA). Daily RSI is rebounding from the oversold zone, while ADX has started shifting into a declining sequence, suggesting that the prevailing downtrend may be losing momentum. A sustained breakout above 23340, followed by a reclaim of 23520 during the week, would strengthen the case for a meaningful trend reversal towards 23700 initially, while 24000 remains the major hurdle for the month. On the derivatives front, 23500 and 23700 remain key weekly resistance levels, as indicated by the OI buildup, while a decisive move above the 23300 Call OI cluster could trigger intense short-covering momentum. On the downside, 23000 remains the key support, while a decisive break below 23100 would invalidate the recent stabilization pattern and could accelerate the decline towards 22880. Until Nifty decisively reclaims 24050, traders should continue to favor stock-specific opportunities with disciplined risk management.

Trade Scanner: ADANIENT, ADANIPOWER, ALKEM, AMBER, AUROPHARMA, DRREDDY, GAIL, HDFCBANK, ICICIPRULI, LAURUSLABS, LTF, MAXHEALTH, PAYTM, VBL, BAJAJ-AUTO, BSE, JINDALSTEL, KAYNES, LTM, NATIONALUM, PFC, TECHM, TORNTPHARM.

RESEARCH DESK: Sacchitanand Uttekar - VP - Research (Derivatives & Technicals)

Disclaimer: Investments in securities market are subject to market risk, read all the related documents carefully before investing.

The securities quoted are for illustration only and are not recommendatory | Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Disclaimer: This document is for private circulation and information purpose only and should not be regarded as an investment, trading, taxation, legal or price? risk management advice. In no circumstances it is considered as an offer to sell or a solicitation of any offer to buy or sell the Equity derivatives mentioned herein. We and our affiliates, group? companies, directors and employees, and directors and employees of our affiliates and group? companies, including persons involved in the preparation or issuance of this material may (a) have positions in Equity (derivatives or physical) mentioned hereby or (b) have other positions which might have conflicting interest with respect to any related information. The information contained hereby may have been taken from sources which we believe are reliable. We do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinion expressed reflects judgments at this date and are subject to change without notice. Risk of loss in Equity derivatives trading can be substantial. Persons trading in Equity Derivatives should consider the suitability of trading based upon their resources, risk appetite and other relevant information; and understand that statements regarding future prospects may not be realized.